Biodesix to Present Seven Abstracts at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy BDSX?
Source: Newsfilter
- Research Showcase: Biodesix will present seven abstracts, including two oral sessions, at the AACR Annual Meeting from April 17-22, 2026, highlighting its capabilities in blood and tissue testing and monitoring, aimed at enhancing collaboration with biopharma and life science partners.
- Technology Platforms: The company will showcase diverse technology platforms, including Bio-Rad's ddPCR™ and Thermo Fisher's Ion AmpliSeq™, which can rapidly deliver clinical test results, supporting tumor and immune profiling, expected to significantly enhance clinical application efficiency and accuracy.
- New Product Pipeline: Biodesix will introduce a novel multi-omic approach to MRD monitoring, integrating genomic and proteomic biomarkers, which is anticipated to provide more sensitive detection capabilities for tumor monitoring, further advancing the company's strategic positioning in precision medicine.
- Clinical Impact: By showcasing over a decade of experience in clinical development and commercialization, Biodesix aims to emphasize the clinical impact of its technologies at AACR, laying the groundwork for future business growth, particularly in personalized medicine and tumor testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDSX
Wall Street analysts forecast BDSX stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.140
Low
20.00
Averages
30.00
High
40.00
Current: 13.140
Low
20.00
Averages
30.00
High
40.00
About BDSX
Biodesix, Inc. is a diagnostic solutions company. It offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule's risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient’s immune system to help guide treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biodesix Earns 2026 USA TODAY Top Workplaces Award
- Employee Engagement Boost: Biodesix has been awarded the 2026 USA TODAY Top Workplaces award due to exceptional employee engagement, with feedback indicating that team members feel cared for and empowered to reach their full potential, enhancing the overall workplace atmosphere.
- Cultural Achievement: Winning this award for three consecutive years reflects Biodesix's core values of trust, collaboration, and shared accountability, with CEO Scott Hutton emphasizing that this recognition stems from genuine employee experiences, further solidifying the company's culture.
- Market Competitive Advantage: The USA TODAY Top Workplaces award not only enhances Biodesix's credibility but also provides a trusted badge for job seekers and customers, signaling that the company values its people and increasing its attractiveness in a competitive market.
- Leader in Diagnostic Solutions: As a leading diagnostic solutions company, Biodesix is committed to improving clinical care and patient outcomes, with its Nodify Lung® and IQLung® products supporting personalized care decisions, thereby amplifying the company's impact in the healthcare sector.
See More
Biodesix to Present Seven Abstracts at AACR Annual Meeting
- Research Showcase: Biodesix will present seven abstracts, including two oral sessions, at the AACR Annual Meeting from April 17-22, 2026, highlighting its capabilities in blood and tissue testing and monitoring, aimed at enhancing collaboration with biopharma and life science partners.
- Technology Platforms: The company will showcase diverse technology platforms, including Bio-Rad's ddPCR™ and Thermo Fisher's Ion AmpliSeq™, which can rapidly deliver clinical test results, supporting tumor and immune profiling, expected to significantly enhance clinical application efficiency and accuracy.
- New Product Pipeline: Biodesix will introduce a novel multi-omic approach to MRD monitoring, integrating genomic and proteomic biomarkers, which is anticipated to provide more sensitive detection capabilities for tumor monitoring, further advancing the company's strategic positioning in precision medicine.
- Clinical Impact: By showcasing over a decade of experience in clinical development and commercialization, Biodesix aims to emphasize the clinical impact of its technologies at AACR, laying the groundwork for future business growth, particularly in personalized medicine and tumor testing.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
BIODESIX INC: WILLIAM BLAIR UPGRADES RATING TO OUTPERFORM
Company Overview: BioDesix is a biotechnology company focused on developing diagnostic tests for lung cancer and other diseases.
Recent Developments: William Blair has raised the performance rating for BioDesix, indicating positive expectations for the company's future growth and performance.
See More
Biodesix Reports Strong Q4 2025 Earnings with Positive EBITDA
- Significant Revenue Growth: Biodesix achieved $28.8 million in revenue for Q4 2025, marking a 41% year-over-year increase, with total fiscal year revenue reaching $88.5 million, up 24%, showcasing strong performance in lung diagnostics.
- Improved Gross Margins: The gross margin for Q4 was 83%, an increase from 81% in the previous quarter, reflecting successful cost control and operational efficiency, which further strengthens the company's financial health.
- Sales Force Expansion: The sales team grew from 85 to 97 representatives, driving test volumes to 18,000, a 23% increase year-over-year, laying a solid foundation for future revenue growth.
- Enhanced Strategic Partnerships: Strategic collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories have bolstered the company’s development services and product pipeline, expected to support future market expansion and technological innovation.
See More
Biodesix Reports Q4 Loss with Revenue Growth
- Financial Performance Improvement: Biodesix reported a fourth-quarter loss of $3.98 million, or $0.49 per share, which is an improvement from last year's loss of $8.25 million and $1.13 per share, indicating progress in cost control.
- Significant Revenue Growth: The company achieved fourth-quarter revenue of $28.76 million, a 40.8% increase from $20.43 million last year, demonstrating strong product demand and an increase in market share.
- Profitability Trend: Although still in a loss position, the significant reduction in losses compared to the previous year reflects improvements in operational efficiency and market strategy, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With ongoing revenue growth and reduced losses, Biodesix's competitiveness in the biotechnology sector is strengthening, which may attract more investor interest in its potential for profitability.
See More
Biodesix Earns 2026 USA TODAY Top Workplaces Award
- Employee Engagement Boost: Biodesix has been awarded the 2026 USA TODAY Top Workplaces award due to exceptional employee engagement, with feedback indicating that team members feel cared for and empowered to reach their full potential, enhancing the overall workplace atmosphere.
- Cultural Achievement: Winning this award for three consecutive years reflects Biodesix's core values of trust, collaboration, and shared accountability, with CEO Scott Hutton emphasizing that this recognition stems from genuine employee experiences, further solidifying the company's culture.
- Market Competitive Advantage: The USA TODAY Top Workplaces award not only enhances Biodesix's credibility but also provides a trusted badge for job seekers and customers, signaling that the company values its people and increasing its attractiveness in a competitive market.
- Leader in Diagnostic Solutions: As a leading diagnostic solutions company, Biodesix is committed to improving clinical care and patient outcomes, with its Nodify Lung® and IQLung® products supporting personalized care decisions, thereby amplifying the company's impact in the healthcare sector.
See More
Biodesix to Present Seven Abstracts at AACR Annual Meeting
- Research Showcase: Biodesix will present seven abstracts, including two oral sessions, at the AACR Annual Meeting from April 17-22, 2026, highlighting its capabilities in blood and tissue testing and monitoring, aimed at enhancing collaboration with biopharma and life science partners.
- Technology Platforms: The company will showcase diverse technology platforms, including Bio-Rad's ddPCR™ and Thermo Fisher's Ion AmpliSeq™, which can rapidly deliver clinical test results, supporting tumor and immune profiling, expected to significantly enhance clinical application efficiency and accuracy.
- New Product Pipeline: Biodesix will introduce a novel multi-omic approach to MRD monitoring, integrating genomic and proteomic biomarkers, which is anticipated to provide more sensitive detection capabilities for tumor monitoring, further advancing the company's strategic positioning in precision medicine.
- Clinical Impact: By showcasing over a decade of experience in clinical development and commercialization, Biodesix aims to emphasize the clinical impact of its technologies at AACR, laying the groundwork for future business growth, particularly in personalized medicine and tumor testing.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
BIODESIX INC: WILLIAM BLAIR UPGRADES RATING TO OUTPERFORM
Company Overview: BioDesix is a biotechnology company focused on developing diagnostic tests for lung cancer and other diseases.
Recent Developments: William Blair has raised the performance rating for BioDesix, indicating positive expectations for the company's future growth and performance.
See More
Biodesix Reports Strong Q4 2025 Earnings with Positive EBITDA
- Significant Revenue Growth: Biodesix achieved $28.8 million in revenue for Q4 2025, marking a 41% year-over-year increase, with total fiscal year revenue reaching $88.5 million, up 24%, showcasing strong performance in lung diagnostics.
- Improved Gross Margins: The gross margin for Q4 was 83%, an increase from 81% in the previous quarter, reflecting successful cost control and operational efficiency, which further strengthens the company's financial health.
- Sales Force Expansion: The sales team grew from 85 to 97 representatives, driving test volumes to 18,000, a 23% increase year-over-year, laying a solid foundation for future revenue growth.
- Enhanced Strategic Partnerships: Strategic collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories have bolstered the company’s development services and product pipeline, expected to support future market expansion and technological innovation.
See More
Biodesix Reports Q4 Loss with Revenue Growth
- Financial Performance Improvement: Biodesix reported a fourth-quarter loss of $3.98 million, or $0.49 per share, which is an improvement from last year's loss of $8.25 million and $1.13 per share, indicating progress in cost control.
- Significant Revenue Growth: The company achieved fourth-quarter revenue of $28.76 million, a 40.8% increase from $20.43 million last year, demonstrating strong product demand and an increase in market share.
- Profitability Trend: Although still in a loss position, the significant reduction in losses compared to the previous year reflects improvements in operational efficiency and market strategy, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With ongoing revenue growth and reduced losses, Biodesix's competitiveness in the biotechnology sector is strengthening, which may attract more investor interest in its potential for profitability.
See More
